A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)

被引：3
|
作者：
Mohan, Sanjay R. [1 ]
Oh, Stephen T. [2 ]
Ali, Haris [3 ]
Hunter, Anthony M. [4 ]
Palandri, Francesca [5 ]
Lamothe, Betty [6 ]
Cui, Yi [6 ]
Seguy, Francis [7 ]
McBride, Amanda [6 ]
Savona, Michael Robert [8 ]
Kiladjian, Jean-Jacques [9 ]
Verstovsek, Srdan [10 ]
机构：
[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA
[2] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA
[3] City Hope Med Ctr, Duarte, CA USA
[4] Emory Univ, Sch Med, Atlanta, GA USA
[5] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy
[6] Incyte Corp, Wilmington, DE USA
[7] Incyte Biosci Int Sarl, Morges, Switzerland
[8] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[9] Hop St Louis, Paris, France
[10] Univ Texas MD Anderson Canc Ctr, Leukemia Dept, Houston, TX 77030 USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-169210
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3943 / 3944
页数：2
相关论文
共 50 条
  • [1] A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)
    Oh, Stephen T.
    Gotlib, Jason
    Mohan, Sanjay
    Ali, Haris
    Asatiani, Ekatherine
    Seguy, Francis
    Zhou, Feng
    Verstovsek, Srdan
    BLOOD, 2020, 136
  • [2] A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104).
    Oh, Stephen T.
    Kiladjian, Jean-Jacques
    Palandri, Francesca
    Gotlib, Jason R.
    Mohan, Sanjay
    Ali, Haris
    Asatiani, Ekatherine
    Seguy, Francis
    Zhou, Feng
    Verstovsek, Srdan
    CANCER RESEARCH, 2021, 81 (13)
  • [3] A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)
    Oh, Stephen
    Kiladjian, Jean-Jacques
    Palandri, Francesca
    Gotlib, Jason
    Mohan, Sanjay
    Ali, Haris
    Asatiani, Ekatherine
    Seguy, Francis
    Zhou, Feng
    Verstovsek, Srdan
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 111 - 112
  • [4] Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF).
    Bose, Prithviraj
    Mohan, Sanjay
    Oh, Stephen
    Gotlib, Jason R.
    Ritchie, Ellen K.
    Shimomura, Taizo
    Ali, Haris
    Boyer, Francoise
    Guglielmelli, Paola
    Hunter, Anthony
    Lamothe, Betty
    Cui, Yi
    Seguy, Francis
    McBride, Amanda
    Palandri, Francesca
    Takeuchi, Masahiro
    Kiladjian, Jean-Jacques
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis
    Mohan, Sanjay
    Oh, Stephen
    Kiladjian, Jean-Jacques
    Takeuchi, Masahiro
    Gotlib, Jason
    Ritchie, Ellen K.
    Shimomura, Taizo
    Guglielmelli, Paola
    Hunter, Anthony M.
    Palandri, Francesca
    Boyer, Francoise
    Rambaldi, Alessandro
    Mori, Takehiko
    Ito, Tomoki
    Lamothe, Betty
    Yang, Yan-Ou
    Cui, Yi
    Seguy, Francis
    McBride, Amanda
    Bose, Prithviraj
    BLOOD, 2023, 142
  • [6] Phase I/II Study of the Activin Receptor-Like Kinase 2 (ALK2) Inhibitor Zilurgisertib (INCB000928, LIMBER-104) as Monotherapy or With Ruxolitinib in Patients With Anemia Due to Myelofibrosis
    Bose, Prithviraj
    Mohan, Sanjay
    Oh, Stephen
    Gotlib, Jason
    Ritchie, Ellen
    Shimomura, Taizo
    Ali, Haris
    Boyer, Francoise
    Guglielmelli, Paola
    Hunter, Anthony
    Lamothe, Betty
    Cui, Yi
    Seguy, Francis
    McBride, Amanda
    Palandri, Francesca
    Takeuchi, Masahiro
    Kiladjian, Jean-Jacques
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S401 - S402
  • [7] Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF)
    Bose, Prithviraj
    Pemmaraju, Naveen
    Schroeder, Kurt
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Daver, Naval
    DiNardo, Courtney D.
    Alvarado, Yesid
    Yilmaz, Musa
    Huynh-Lu, Julie
    Qiao, Wei
    Wang, Xuemei
    Matamoros, Aurelio
    Zhou, Lingsha
    Pierce, Sherry
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2017, 130
  • [8] A Phase 2 Study of the Safety and Efficacy of INCB050465 in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)
    Daver, Naval
    Dao, Kim-Hien
    Assad, Albert
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S351 - S351
  • [9] RUXOLITINIB (RUX) IN COMBINATION WITH 5-AZACYTIDINE (AZA) AS THERAPY FOR PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
    Daver, N.
    Cortes, J.
    Zhou, L.
    Pemmaraju, N.
    Jabbour, E.
    Borthakur, G.
    Estrov, Z.
    Garcia-Manero, G.
    Kantarjian, H.
    Verstovsek, S.
    HAEMATOLOGICA, 2015, 100 : 161 - 162
  • [10] Real-world disease burden for patients (pts) with myelofibrosis (MF) treated with ruxolitinib (RUX).
    Gerds, Aaron Thomas
    Kish, Jonathan
    Parikh, Kejal
    Liassou, Djibril
    Miller, Talia
    Copher, Ronda
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345